#FDA Approves #Merck’s #KEYTRUDA® (#Pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic #CutaneousSquamousCellCarcinoma (cSCC) that is Not Curable by Surgery or Radiation $MRK https://t.co/m4zfnNZUMj